ReviewFrontiers in medicine2026
Blood-based tumor biomarkers: integrating biological layers and analytical strategies for precision cancer detection.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood-based cancer biomarkers promise minimally invasive, longitudinal monitoring, yet their clinical utility varies profoundly by analyte class, disease stage, and analytical methodology. This Review critically evaluates six circulating biomarker classes, such as CTCs, ctDNA, cfDNA methylation, exosomes, circulating miRNAs, and tumor-educated platelets-moving beyond a descriptive catalog to a comparative analysis of their performance characteristics. We find that the dominant challenge is no longer signal detection per se, but rather signal interpretation in the presence of biological confounders like clonal hematopoiesis and pre-analytical variability. We argue that a disciplined pairing of a biomarker's biological origin with the physico-chemical principles of its detection platform is the primary determinant of assay robustness. The Review concludes by outlining a pragmatic framework for integrating orthogonal biomarker readouts, emphasizing that how we combine signals is a more pressing question than how many markers we can measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.